mRNA therapies
Arcturus Prunes Early-Stage Pipeline to Focus on mRNA Therapies
Arcturus Therapeutics; pipeline reduction; mRNA therapies; cystic fibrosis; ornithine transcarbamylase deficiency; Kostaive; vaccine programs; biotech strategy; cash runway
Moderna Co-Founder Kenneth Chien’s New Biotech Secures $950M RNA Deal with Etherna
Kenneth Chien, Moderna, Etherna, RNA deal, biotech, mRNA therapies